Provider Briefing: Prempro 0.45/1.5 28 Day Supply in 2026

If your patients are reporting difficulty filling prescriptions for Prempro 0.45/1.5 28 Day, the reports are consistent with a broader pattern of intermittent availability that has affected this product over the past year. This briefing provides a concise overview of the current supply picture, prescribing considerations, and resources available to support continuity of care.

Current Supply Status

As of March 2026, Prempro 0.45/1.5 28 Day is not listed on the FDA drug shortage database. However, real-world availability has been inconsistent across pharmacy networks. Pfizer, the sole manufacturer, has not issued a formal supply disruption notice, but distribution variability means that pharmacies in some regions have adequate stock while others — particularly chain pharmacies with automated inventory systems — frequently show the product as unavailable.

Key supply factors:

• Single-source product: No FDA-approved generic exists for Prempro in any strength. Pfizer remains the sole manufacturer.
• Wholesale distribution gaps: Supply inconsistencies appear to originate at the distributor level rather than representing a true manufacturing stoppage.
• Strength-specific variability: The 0.45/1.5 mg strength may be affected differently than other Prempro strengths (0.3/1.5, 0.625/2.5, 0.625/5), as pharmacy stocking decisions vary by local demand.

Timeline and Context

Prempro has been on the market since 1995. While it has never been subject to a prolonged formal FDA shortage, intermittent availability reports have increased since 2023, likely reflecting:

• Ongoing supply chain normalization challenges post-pandemic
• Pfizer's portfolio prioritization decisions
• Increased demand as menopause awareness and HRT acceptance have grown following updated professional society guidance
• Lack of generic competition to buffer demand fluctuations

Prescribing Implications

For patients currently stable on Prempro 0.45/1.5, the clinical priority is maintaining treatment continuity. Abrupt discontinuation of combined HRT can result in rapid return of vasomotor symptoms and, in patients using it for osteoporosis prevention, potential acceleration of bone loss.

Considerations when a patient cannot fill their Prempro 0.45/1.5 prescription:

Same-Class Substitutions

• Premphase (CE 0.625 mg / MPA 5 mg cyclic): Same active ingredients, different dosing schedule and higher doses. Suitable for patients who may tolerate cyclic progestin.
• Activella (estradiol 1 mg or 0.5 mg / norethindrone acetate 0.5 mg or 0.1 mg): Oral continuous combined HRT with generic available. Good option when cost or availability is a barrier.
• Climara Pro (estradiol/levonorgestrel transdermal patch): Weekly patch delivery. Preferred for patients with hepatic concerns, hypertriglyceridemia, or VTE risk factors where transdermal delivery offers potential advantages over oral estrogen.
• Angeliq (drospirenone/estradiol): Oral continuous combined HRT with mild anti-mineralocorticoid effects. Monitor potassium in patients with renal impairment or those on ACE inhibitors/ARBs.

Component-Based Approach

Prescribing separate conjugated estrogens (Premarin 0.45 mg) and medroxyprogesterone acetate (generic Provera 1.5 mg) provides an equivalent regimen using the same active ingredients. Generic MPA is widely available and inexpensive. Premarin availability may also vary, but less so than the combination product.

Availability and Access Tools

Several tools can help your practice and patients navigate availability:

• Medfinder for Providers: Real-time pharmacy inventory search. Allows providers and staff to quickly identify pharmacies with Prempro 0.45/1.5 in stock, reducing callbacks and pharmacy transfers.
• FDA Drug Shortage Database: Monitor for formal shortage listings at accessdata.fda.gov.
• ASHP Drug Shortage Resource Center: Additional tracking and clinical alternatives at ashp.org/drug-shortages.

Cost and Access Considerations

The cash price for Prempro 0.45/1.5 28 Day ranges from approximately $256 to $370 per month. For patients facing cost barriers:

• Pfizer Copay Savings Card: Up to $110 savings per fill for commercially insured patients. Available through Pfizer's HCP portal or GoodRx.
• Pfizer RxPathways: Patient assistance program for uninsured/underinsured patients (1-844-989-7284). May provide medication at no cost for eligible patients.
• Pharmacy discount programs: SingleCare, GoodRx, and similar programs may reduce cash prices to $237–$280 per 28-day supply.
• Generic alternatives: If switching is clinically appropriate, generic estradiol/norethindrone acetate (generic Activella) or separate generic Provera + Premarin can significantly reduce costs.

For detailed patient-facing cost information, see: How to save money on Prempro 0.45/1.5 28 Day.

Looking Ahead

No generic Prempro is expected in the near term. The supply situation is likely to remain variable as long as Pfizer is the sole manufacturer. Practices should consider:

• Proactively discussing backup plans with patients on Prempro during routine visits
• Documenting alternative preferences in the patient chart for rapid switching if needed
• Encouraging patients to use Medfinder for real-time availability checks
• Considering whether patients new to HRT might be better started on a product with generic availability

Final Thoughts

The Prempro 0.45/1.5 availability situation in 2026 requires proactive management rather than reactive scrambling. By having alternative strategies documented and using real-time tools like Medfinder for Providers, clinicians can minimize treatment disruptions and maintain patient confidence in their menopause care.

For a practical guide on helping patients locate their medication, see: How to help your patients find Prempro 0.45/1.5 in stock.